Ultragenyx Pharmaceutical RARE announced that the FDA has granted the Breakthrough Therapy designation to its investigational ...

The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.

The drug inhibits sclerostin, a protein that causes the body to produce less bone tissue. By blocking this protein, the hope is that these patients will produce more, stronger bone tissue. In a ...

After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney ...

A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small ...

Treatment with AGA2118, a bispecific antibody targeting both sclerostin and DKK1, led to rapid and durable increases in bone formation, decreases in bone resorption, and improvements in bone mineral ...

Ahmedabad: Zydus Lifesciences Ltd, Ahmedabad has signed a collaborative research agreement with Central Drug Research ...

NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RARE), a biopharmaceutical company focused on the development of ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its ...

The UT administration's Drugs Control Wing conducted extensive raids on chemist shops in Manimajra, uncovering violations including unlicensed drug sales and absence of qualified pharmacists.

Sensex Today | Stock Market LIVE Updates | Domestic stocks maintained their upward trend, reaching new highs as favorable ...